INTRODUCTION {#s1}
============

In recent years, genome-wide association studies (GWAS) have identified thousands of new susceptibility loci for common diseases, including dozens for celiac disease (CeD) ([@DDT619C1],[@DDT619C2]). CeD is an immune-mediated disease triggered by gluten in the diet of genetically susceptible individuals, and it is strongly correlated with the presence of specific HLA-DQ isotypes, which are necessary but not sufficient to lead to the disease ([@DDT619C3]). In a previous GWAS, we identified 26 non-human leukocyte antigen (non-HLA) loci with small effect size that explain part of the heritability of CeD ([@DDT619C4]). Recently, we used the Immunochip ([@DDT619C5]) and discovered 13 additional susceptibility loci, as well as fine mapping \>50% of all 40 loci ([@DDT619C6]). In total, we reported 39 non-HLA susceptibility loci, which together with the HLA locus, explain 50% of CeD heritability ([@DDT619C6]). The strongest non-HLA association signal maps to a 70 kb linkage disequilibrium (LD) block in intron 2 of the *LPP* gene. Conditional analysis of this highly associated variant revealed no other signals of association, indicating a single-associated haplotype in this locus.

The LPP gene has also been reported to be associated with vitiligo ([@DDT619C7]), an autoimmune disease, in which the top SNP is located in the same haplotype as the CeD top SNP (*r*^2^ = 0.8 and *D*′ = 0.9). The LPP gene is involved in cell motility and cell--cell adhesion, which is crucial to maintaining the barrier integrity of epithelial monolayers, especially in the small intestine. It might therefore play a role in the pathogenesis of CeD ([@DDT619C8],[@DDT619C9]).

Our aim was to fine map the CeD-associated 70 kb intronic region at the *LPP* locus and to identify possible functional variants. We used data from six different CeD populations (UK, Dutch, Polish, Spanish, Italian and Indian) genotyped on the Immunochip array. Further, a haplotype analysis was performed, followed by haplotype association testing in each population separately. Finally, we intersected the fine-mapped region with functional annotation data from the ENCODE project ([@DDT619C10]). This allowed us to refine the 70 kb region of association to a 25-fold smaller region of 2.8 kb enriched with regulatory elements, where we identified one SNP predicted to change transcription-factor-binding motif.

RESULTS {#s2}
=======

Meta-analysis identified a single variant at *LPP* locus {#s2a}
--------------------------------------------------------

In order to fine map the 70 kb *LPP* LD region, we performed a meta-analysis on a large cohort of 25 169 individuals, who had been genotyped by Immunochip (Table [1](#DDT619TB1){ref-type="table"}, [Supplementary Material, Table S1](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)). The SNP with the highest association with CeD was located within intron 2 of the *LPP* locus (rs2030519; *P* = 1.76 × 10^−49^; OR = 0.75, 95% CI 0.72--0.78) (Fig. [1](#DDT619F1){ref-type="fig"}A and B), where the minor allele G is more frequent in controls than in CeD cases, suggesting that the allele has a protective effect. To check for possible additional independent signals, we performed a conditional analysis on this top SNP, but did not uncover any novel significant signals ([Supplementary Material, Fig. S1](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)), indicating association to a single, common haplotype. Table 1.Population-specific top SNPs compared with the meta-top SNPPopulationCasesControlsSNPsBP (Hg19)Minor alleleMajor alleleMAFMAF (cases)MAF (controls)OR (95% CI)*Pr*^2^ rs2030519*D*′ rs2030519Meta-analysis12 51312 656rs2030519188119901GA0.40.410.480.75 (0.72--0.78)1.76E−4911UK77288274rs2030519188119901GA0.40.40.480.74 (0.70--0.77)4.56E−3811Italy14861270rs9834159188115232TA0.40.450.470.74 (0.67--0.83)2.11E−070.990.99The Netherlands11501173rs60946162188133336TC0.40.380.430.80 (0.73--0.93)0.0023530.80.96Spain1131662rs60946162188133336TC0.40.440.490.78 (0.67--0.89)0.00048360.80.96Poland521541rs2103025188070570TC0.10.160.121.4 (1.12--1.85)0.0041460.0080.2India497736rs11923721188100188TA0.080.090.071.4 (1.05--2.58)0.02070.0450.91[^3] Figure 1.Fine mapping of the *LPP* region. (**A**) Localization of the *LPP* gene on chromosome 3 and the LD region. (**B**) Meta-analysis of imputation and Immunochip (iCHIP) results. Open circles are SNPs genotyped by the iCHIP, black dots represent SNPs imputed by GoNL and gray dots represent SNPs imputed by the 1000 Genomes Project (1kG). (**C**) SNPs in the fine-mapping region overlapping to ENCODE regulatory regions, including DNase I hypersensitive sites, histone modifications determined by ChIP-seq and transcription factor-binding site ChIP signals. Signal peaks are depicted as darker regions. Evolutionary conserved sites are also shown. \*14 SNPs that construct the core-haplotype. \*\*7 SNPs in orange differentiate the risk from the non-risk haplotype. The functional candidate SNP rs4686484 is depicted in red. The top meta-analysis SNP is in blue. (**D**) Sequencing of the functional candidate SNP predicted to change the binding site of the shown transcription factors. Prot, protective; Ref, reference.

Imputation confirmed the meta-analysis results {#s2b}
----------------------------------------------

In order to test whether any non-genotyped variants were more strongly associated with CeD than the top SNP, we imputed genotypes using two different reference panels \[1000 Genomes Project and Genome of the Netherlands (GoNL)\]. This analysis resulted in an additional 397 SNPs (254 SNPs from the 1000 Genomes project data, 110 SNPs from the GoNL study, with 33 SNPs identified by both). We then performed a meta-analysis on both the known, as well as the imputed, SNPs. This confirmed that SNP rs2030519 was the strongest CeD-associated SNP in the *LPP* locus (*P* = 1.79 × 10^−49^, OR = 0.75, 95% CI 0.72--0.78) in this region (Fig. [1](#DDT619F1){ref-type="fig"}B).

Association analysis in different populations indicated different top SNPs {#s2c}
--------------------------------------------------------------------------

Since the meta-analysis identified rs2030519 as the most strongly associated SNP, we tested whether rs2030519 was also the top SNP in the six separate populations. The top SNP was confirmed as the strongest associated SNP only in the UK population (the largest cohort) (*P* = 4.56 × 10^−38^, OR = 0.74, 95% CI 0.70--0.77), whereas in the other five populations, different top SNPs were identified (Table [1](#DDT619TB1){ref-type="table"}). In the Italian population, the top SNP was rs9834159 (*P* = 2.11 × 10^−7^, OR = 0.74, 95% CI 0.67--0.83), and in the Dutch and Spanish cohorts the top SNP was rs60946162 (*P* = 0.002, OR = 0.8, 95% CI 0.73--0.93 and *P* = 0.0004, OR = 0.78, 95% CI 0.67--0.89, respectively). The top SNPs in the Polish cohort (rs2103025; *P* = 0.004, OR = 1.4, 95% CI 1.12--1.85) and in the Indian cohort (rs11923721; *P* = 0.02, OR = 1.4, 95% CI 1.05--2.58) showed association in opposite directions (Table [1](#DDT619TB1){ref-type="table"}) to the top SNPs in the other four cohorts (UK, Italy, Netherlands and Spain). These results suggest that there could be population-specific, CeD-associated alleles.

Haplotype analysis suggested a common CeD-associated haplotype {#s2d}
--------------------------------------------------------------

The existence of different CeD-associated top SNPs in different populations may suggest that these SNPs could be tagging a common functional variant on a common haplotype. We therefore included all the genotyped SNPs within a 250 kb window around the top SNP (rs2030519) from the meta-analysis, and generated haplotypes in populations that showed significant *P*-value with rs2030519 after a Bonferroni correction for the six populations (*P* \< 0.008). Next, we tested the association of haplotypes with CeD using logistic regression in the separate populations. The Indian and Polish cohort were excluded from haplotype association analysis ([Supplementary Material, Table S3](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)). We therefore performed the haplotype association test in a meta-analysis of the four remaining populations together (UK, Italy, Netherlands and Spain). The biggest haplotype size (53.7 kb) was found in the Dutch cohort (Table [2](#DDT619TB2){ref-type="table"}) and the smallest haplotype (3.1 kb, Table [2](#DDT619TB2){ref-type="table"}) was found in the UK population, which was the largest cohort ([Supplementary Material, Table S1](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)). By looking at the most strongly associated haplotype in each of the European populations, we identified a core haplotype of 4.1 kb containing 14 SNPs (Table [2](#DDT619TB2){ref-type="table"} and [Supplementary Material, Fig. S2 and Table S4](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)). Table 2.Haplotypes analysis per populationPopulationNSNPCHRBP1 (HG19)BP2 (HG19)SNP1SNP2HAPLOTYPEFreqFreq casesFreq controlsOR*P*Haplotype size (kb)The Netherlands533188083987188137767rs76211316rs13319297CTGTGCGGATATTATGGCGGCA CCCTGTA[CGATCTGGC]{.ul}**G**[CAT]{.ul}GTTCGCCTTAA0.380.35950.40.8460.0054953.7Spain433188087628188122978rs9851967rs2049218TGCGGATATTATGGCGGCACCCT CGTA[CGATCTGGC]{.ul}**G**[CAT]{.ul}GTT0.4420.41840.48340.7680.00016835.3Italy203188114458188122978rs12107245rs2049218CGTA[CCGATCTGGC]{.ul}**G**[CAT]{.ul}GT0.4530.42260.48940.7595.77E−078.5UK113188116784188119901rs9820681rs2030519[ACGATCTGGC]{.ul}**G**0.4470.40940.48180.7431.11E−383.1Meta-analysis^a^143188116907188121019rs7634898rs12634152[CCGATCTGGC]{.ul}**G**[CAT]{.ul}0.4540.42190.48570.7711.35E−444.8[^4][^5]

Seven SNPs differentiate risk and non-risk haplotypes {#s2e}
-----------------------------------------------------

In order to see whether differences in the risk and protective haplotypes across populations could reduce the size of this region, we performed a haplotype logistic regression using the 14 SNPs (Table [3](#DDT619TB3){ref-type="table"}) in each population separately, as well as in all four populations together (Table [3](#DDT619TB3){ref-type="table"}). By comparing the haplotypes obtained, we found a common, associated haplotype present in all the populations (Table [3](#DDT619TB3){ref-type="table"}). Seven of the 14 SNPs showed minor alleles present in the protective haplotype, but absent in the risk haplotype (Table [3](#DDT619TB3){ref-type="table"}). This approach reduced the core haplotype down to a 2.8 kb region (chr3: 188117070--188119901, NCBI build 37) and suggests that this region might well harbor the causative variant for CeD (Fig. [1](#DDT619F1){ref-type="fig"}C). Table 3.Haplotype association analysis in the 14 SNPs from the core haplotypePopulationrs7634898rs7635012rs6790260rs28637341rs6444284rs6444285rs4686483rs4686484rs6778720rs2030520**rs2030519**rs6785284rs1035765rs12634152FrequencyFreq casesFreq controlsOR*P*Meta-analysis^a^**CCG**AT**CTGGCG**CAT0.4540.42190.48570.7689.41E−45**CC**C**TC**TAAATA**TTC**0.4350.46090.40811.258.70E−32TACATTAAATACA**C**0.04770.051430.0441.180.000115**C**ACATTAAATACAT0.06190.063750.060031.060.111UK**CCG**AT**CTGGCG**CAT0.4470.40940.48180.742.84E−38**CC**C**TC**TAAATA**TTC**0.4380.46730.411.281.45E−25TACATTAAATACA**C**0.04650.050920.04231.220.000294**C**ACATTAAATACAT0.06730.070460.064421.090.051Italy**CCG**AT**CTGGCG**CAT0.4870.45560.52480.7554.12E−07**CC**C**TC**TAAATA**TTC**0.4310.45990.3981.294.67E−06**C**ACATTAAATACAT0.02920.031310.026771.20.262TACATTAAATACA**C**0.04830.050510.045671.090.503The Netherlands**CCG**AT**CTGGCG**CAT0.4370.41430.45950.8430.00482**CC**C**TC**TAAATA**TTC**0.4560.47960.43351.20.00277**C**ACATTAAATACAT0.05750.056960.057970.9450.659TACATTAAATACA**C**0.04740.047830.046461.020.879Spain**CCG**AT**CTGGCG**CAT0.4880.46540.52570.7830.000551**CC**C**TC**TAAATA**TTC**0.40.41490.37541.170.0245TACATTAAATACA**C**0.04830.052750.040791.30.131**C**ACATTAAATACAT0.06230.066050.055891.210.199[^6][^7]

Annotation of established functional elements in the core haplotype region {#s2f}
--------------------------------------------------------------------------

To investigate whether the seven core-haplotype SNPs are located within known functional elements, they were subjected to HaploReg. The 2.8 kb region contained open chromatin regions, as identified in 19 cell lines of the ENCODE Project cell line panel (Fig. [1](#DDT619F1){ref-type="fig"}C and [Supplementary Material, Table S5](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)). Of the seven SNPs, six (rs6790260, rs6444285, rs4686483, rs4686484, rs6778720 and rs2030520) mapped to regions annotated with histone modifications H3K27ac, H3K4m1, H3k4 m2, H2A.Z and EZH2 identified in B- and T-cells (Fig. [1](#DDT619F1){ref-type="fig"}C and [Supplementary Material, Table S5](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)). Interestingly, SNP rs4686484 (*P* = 3.12 × 10^−49^), which is in high LD with the top-meta SNP, rs2030519 (*r*^2^ ≥ 0.9 and *D*′ = 1), maps to DNase hypersensitive sites in multiple cell lines (including B- and T-cells). In addition, it maps to overlapping DNA fragments that were individually isolated by chromatin immunoprecipitation (ChIP) using antibodies against BATF and PU.1 (Fig. [1](#DDT619F1){ref-type="fig"}C and [Supplementary Material, Table S5](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)). Hence, SNP rs4686484 is highly conserved (Fig. [1](#DDT619F1){ref-type="fig"}C, [Supplementary Material, Table S5](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)) and HaploReg suggested that this SNP changes the consensus-binding motif of the transcription factors IRF4, IRF11, Nkx2.7 and Nkx2.9 (Fig. [1](#DDT619F1){ref-type="fig"}D, [Supplementary Material, Table S5](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)).

In order to test whether the SNP rs4686484 can be prioritized as the only candidate SNP without performing haplotype analysis, we subjected 174 SNPs present in the original 70 kb region to HaploReg annotation ([Supplementary Material, Fig. S4](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)). We found 12 SNPs in high LD with rs4686484 (*r*^2^ ≥ 0.7 and *D*′ = 1) overlapping with regulatory elements characterized by open chromatin, histone modification and transcription factor binding. However, it is not clear which of these 12 SNPs are functionally involved in CeD pathogenesis. Therefore, the fine mapping by haplotype analysis helped us to prioritize the most likely functional SNP even though the associated region contained more than one SNP with similar regulatory potential.

Sanger sequencing to identify novel variants {#s2g}
--------------------------------------------

In order to test whether the highly conserved regulatory region contained novel variants in LD with SNP rs4686484, we sequenced 391 bp around this functional SNP (chr3: 188118290--188118680, NCBI build 37) in 210 Dutch individuals (117 cases and 93 controls). This did not identify any novel variants in the region, which was in concordance with GoNL data ([@DDT619C11]). Although two SNPs (rs147428170 and rs148483836) are located in this region (according to the 1000 Genomes Project), we were not able to confirm them in the 210 individuals we sequenced, probably because these two SNPs are very rare (minor allele frequency, MAF \< 0.001) in the CEU population. We therefore consider SNP rs4686484 to be the main functional candidate ([Supplementary Material, Table S6](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)).

Low expression of the *LPP* gene in biopsies from CeD patients {#s2h}
--------------------------------------------------------------

In order to test whether *LPP* gene levels are affected in the CeD status, microarray expression analysis was performed on 25 duodenal biopsies (12 celiac patients with villous atrophy and 13 healthy controls) ([Supplementary Material, Methods](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)). This showed a lower expression of the *LPP* gene in biopsies of celiac patients with villous atrophy (Marsh III stage) compared with healthy controls ([Supplementary Material, Fig. S3](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)). These results suggest *LPP* is a causative gene in the pathogenesis of CeD.

DISCUSSION {#s3}
==========

We aimed to refine a 70 kb LD region of the *LPP* gene, previously reported as the strongest non-HLA-associated locus in CeD, and to identify possible functional variants. We analyzed genotype data obtained with Immunochip in six-independent populations in this region ([@DDT619C6]). A meta-analysis on the six sets of genotyped and imputed data confirmed that the strongest association was to the SNP rs2030519 (*P* = 1.79 × 10^−49^) located in intron 2 of the *LPP* locus (Fig. [1](#DDT619F1){ref-type="fig"}A and B). Subsequent conditional analysis on this SNP indicated no other independent associations and suggested the presence of a single, common risk haplotype in this locus ([Supplementary Material, Fig. S1](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)).

It has been suggested that disease etiology is common between populations, but that risk variants are often population specific ([@DDT619C12]). Here, we performed a population-specific association analysis to test the genetic heterogeneity between six populations. Except for the UK population, their top SNPs differed from the meta-analysis top SNP (Table [1](#DDT619TB1){ref-type="table"}). In addition, except for the Polish top SNP, the top SNPs of the other populations were in LD with the meta-analysis top SNP (Table [1](#DDT619TB1){ref-type="table"}), suggesting a common-associated haplotype in these populations.

Haplotype analysis using different populations has been shown to be a suitable strategy for fine-mapping associated regions ([@DDT619C13]). Since haplotypes characterize the exact organization of alleles along the chromosome ([@DDT619C14]), more information can be incorporated into the association tests by constructing haplotype blocks from SNPs ([@DDT619C15]). Accordingly, in this study, we were able to find a core haplotype of 4.1 kb by comparing the most strongly-associated haplotype per population in four Caucasian cohorts, which indicated a common associated haplotype between these populations (Fig. [1](#DDT619F1){ref-type="fig"}C, Table [2](#DDT619TB2){ref-type="table"}). In addition, we observed that the sample size of the study cohort is very important to narrow down the associated regions. By analyzing only the two largest populations (UK and Italy), we found a haplotype with a more similar size of 4.8 kb than when we investigated all the populations together ([Supplementary Material, Fig S2](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)). However, only by adding the other populations, we were able to compare risk and protective haplotypes, and finally pinpoint seven SNPs that differentiate the risk haplotype from the non-risk haplotype across different populations (Fig. [1](#DDT619F1){ref-type="fig"}C, Table [3](#DDT619TB3){ref-type="table"}). This helped us to refine the associated region down to 2.8 kb, where a functional variant might be located.

It has been shown that there is an enrichment of regulatory elements from the ENCODE project overlapping SNPs identified by GWAS ([@DDT619C10],[@DDT619C16]). To prioritize SNPs in the 2.8 kb region that could have a functional effect, we intersected all seven SNPs in the 2.8 kb region with regulatory information available from the ENCODE Project ([@DDT619C10]). In the end, we were able to identify six out of seven SNPs that mapped to a regulatory region, either to DNase hypersensitive sites or regions with enhancers histone modifications (Fig. [1](#DDT619F1){ref-type="fig"}C, [Supplementary Material, Table S4](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)). One SNP, rs4686484, directly overlapped these two regulatory sites and also mapped to transcription-factor-binding sites (Fig. [1](#DDT619F1){ref-type="fig"}C). The G allele at rs4686484 was predicted to interfere with the consensus motives of transcription factors IRF4, IRF11, Nfx2.7 and Nfx2.9 (Fig. [1](#DDT619F1){ref-type="fig"}D). Interestingly, IRF4 has been described as interacting with PU.1 ([@DDT619C17]), and since the G allele of the functional SNP interferes with IRF4 binding, it is possible that this SNP could affect IRF4-mediated PU.1 binding. Whether this alteration would increase or decrease the expression of *LPP* remains to be tested. Moreover, the *IRF4* gene was also reported to be associated with CeD ([@DDT619C6]), and it could be that it somehow interacts with the *LPP* gene. To investigate this, we used Genenetwork ([www.genenetwork.nl](www.genenetwork.nl)) and DAVID ([@DDT619C18]); however, we did not find any shared pathways between *LPP* and *IRF4* (results not shown).

The lack of any novel variants on sequencing, as well as the many overlapping layers of regulatory information within this highly conserved regulatory region, confirmed rs4686484 as the most likely functional SNP ([Supplementary Material, Table S6](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)). However, we did not find any eQTL effect for SNP rs4686484 in a peripheral blood dataset of 1240 samples ([@DDT619C19]). We were therefore unable to establish a causal link between the prioritized functional SNP and the *LPP* gene. Nonetheless, microarray analysis in duodenal biopsies showed that the *LPP* gene is down-regulated in severe CeD cases (villous atrophy, Marsh III) compared with healthy individuals ([Supplementary Material, Fig. S3](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)). We examined the expression level of *LPP* in biopsies from individuals genotyped for the rs4686484 SNP, but found no significant difference, most likely due to our very limited sample size (*n* = 25) (results not shown). Nevertheless, this result is in agreement with a previous study that also showed lower expression of the *LPP* gene in biopsies of CeD patients ([@DDT619C20]), suggesting that *LPP* is the most plausible causative gene in this locus.

The fact that many regulatory elements in B-cells from the ENCODE project overlap with the fine-mapped region (Fig. [1](#DDT619F1){ref-type="fig"}C, [Supplementary Material, Table S5](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)) suggests that our functional SNP may impact gene expression in B-cells. Although CeD is known to be mainly a T-cell disorder, the role of B-cells in the pathogenesis of CeD is being increasingly recognized ([@DDT619C21],[@DDT619C22]). It has been suggested that B-cells, in combination with the enzyme transglutaminase 2, can present gluten peptides to gluten reactive T-cells ([@DDT619C22]). Our data suggest that B-cells are an important cell type for performing functional assays to better understand the role of the *LPP* locus in CeD pathogenesis.

Since the prioritized SNP rs4686484 has a regulatory function, it may affect other genes outside of the LD block as well. In this context, the *BCL6* gene, located 658.7 kb away from the candidate SNP, is a plausible candidate. Recently, a meta-analysis for allergic sensitization identified an SNP (rs9865818) located in the *LPP* gene, and in LD with our candidate SNP rs4686484 (*r*^2^ = 0.75, *D*′ = 0.93), that showed a *cis*-eQTL effect specifically for B-cells in the *BCL6* gene ([@DDT619C23]). This suggests that it is still possible that the SNP rs4686484, or an SNP in the same haplotype, can act by regulating *BCL6* specifically in B-cells. Additionally, to support this idea, it is known that *IRF4* and *BCL6* have a very close interaction. We therefore analyzed the expression data of *BCL6* in biopsies similar to *LPP*, but found no difference between CeD and healthy control biopsies ([Supplementary Material, Fig S5](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)). This finding suggests that *LPP* is a candidate gene. However, we do not have any conclusive evidence that links our possible causative SNP with the *LPP* gene. Hence, more eQTL studies in B-cell-specific datasets are necessary to establish a true causal gene.

In summary, we were able to narrow down an intronic region strongly associated with CeD from 70 to 2.8 kb. By integrating data from the ENCODE project with our findings, we identified six SNPs that overlap regulatory sites (Fig. [1](#DDT619F1){ref-type="fig"}C), with one, rs4686484, having a possible biological function. In addition, gene expression data from patient biopsies suggested that the *LPP* gene might be involved in the pathogenesis of CeD. Further functional studies are therefore warranted to validate our findings.

MATERIALS AND METHODS {#s4}
=====================

Study population {#s4a}
----------------

The CeD study population (12 513 patients and 12 656 controls) included the samples described previously ([@DDT619C6]), with additional samples in each population that had since become available ([Supplementary Material, Table S1](http://hmg.oxfordjournals.org/lookup/suppl/doi:10.1093/hmg/ddt619/-/DC1)). Affected individuals were diagnosed as patients with CeD according to standard clinical, serological and histo-pathological criteria, including a small intestinal biopsy ([@DDT619C24]). DNA samples were isolated from blood, lympho-blastoid cell lines or saliva, as indicated by Trynka *et al*. ([@DDT619C6]). The details of the SNP probes present on the Immunochip array, and of the genotyping and quality control filters, have been reported previously ([@DDT619C6]). All the subjects sampled for this project provided informed consent, and the study was approved by the ethics committees or institutional review boards of the hospitals where the samples were collected.

Association analyses {#s4b}
--------------------

A meta-analysis was performed in the 70 kb *LPP* LD region (chr3: 188069360--188139629, NCBI build 37) using PLINK ([@DDT619C25]). Gender and the country of origin were included as covariates. PLINK was also used for a stepwise, conditional logistic regression of the most associated SNPs showing the highest meta-analysis association *P*-value. In order to assess the association per population, we performed a logistic regression on each population separately, using gender as a covariate.

Imputation {#s4c}
----------

SNPs were imputed across the *LPP* LD region using data from the 1000 Genomes Project ([@DDT619C26]) and from the GoNL ([@DDT619C11]) as reference panels. Before imputation, the data were filtered for SNPs with an MAF \>0.01 and deviations from Hardy--Weinberg equilibrium in controls (*P* \> 0.0001), and subsequently aligned to the forward strand. The data were analyzed in batches comprising 500 samples and 2000 SNPs, with an overlap of 500 SNPs. Phasing was performed using MACH 1.0.18 ([@DDT619C27]) applying 20 rounds of 200 states. We used MOLGENIS compute ([@DDT619C28]) imputation pipeline to generate our scripts and monitor the imputation. IMPUTE2 ([@DDT619C29]) was used in both reference panels, applying its default options. Finally, a meta-analysis on all the cohorts together was performed, as described above.

Haplotype analysis {#s4d}
------------------

Haplotype analyses were performed using PLINK v1.7 ([@DDT619C25]), where haplotype blocks were generated within a 250 kb window harboring the most significant SNP from the meta-analysis. Next, a Bonferroni correction was performed for the six populations tested and only the populations that had the top meta-analysis SNP with significant *P*-value (0.008) were included for further analysis. Afterwards, a haplotype logistic regression analysis in each population was performed. In order to see differences in the risk versus non-risk haplotypes, SNPs located in the core haplotype (an overlapping, shared haplotype region in all populations) were used to perform a haplotype association test per population.

Functional annotation of variants {#s4e}
---------------------------------

The regulatory regions overlapping with the identified SNPs and proxies (*r*^2^ ≥ 0.9, 1000 Genomes project-CEU), and present in the fine-mapped haplotype, were annotated using HaploRegv2 ([@DDT619C30]) default settings. HaploReg takes the SNPs on the haplotype block, and using LD information from the 1000 Genomes Project, intersects these SNPs with functional regions identified by the ENCODE project ([@DDT619C10]). In addition, it predicts the effects of an SNP in a regulatory region based on a library of position-weighted matrices collected from JASPER ([@DDT619C31]), TRANSFAC ([@DDT619C32]) and protein-binding microarray experiments ([@DDT619C33]--[@DDT619C35]). HaploReg v2 also provides annotation of mammalian conservation based on GERP ([@DDT619C36]) and Si-phy ([@DDT619C37]) algorithms. UCSC Genome Browser was used to look for intersections between SNPs and regulatory elements from the most recent data of the ENCODE project ([@DDT619C10]).
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